Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andy Barker

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Drug Discovery Today|November 3, 2012
Expanding medicinal chemistry spaceAndy Barker, Jason G Kettle, Thorsten Nowak, et al.
Applied and Environmental Microbiology|July 13, 2026
Supporting crop yields under climate change by engineering innate soil microbiomesAnaïs Chanson, Iain J Gould, Åsgeir R Almås, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Drug Discovery Today|November 3, 2012
Expanding medicinal chemistry spaceAndy Barker, Jason G Kettle, Thorsten Nowak, et al.
Applied and Environmental Microbiology|July 13, 2026
Supporting crop yields under climate change by engineering innate soil microbiomesAnaïs Chanson, Iain J Gould, Åsgeir R Almås, et al.
Molecular Cancer Therapeutics|June 11, 2009
AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenograftsKate F Byth, Andrew Thomas, Gareth Hughes, et al.
Pageof 1